IL6R and breast carcinoma: Tocilizumab, an IL-6Rα mAb originally FDA-approved for rheumatoid arthritis, is being investigated in combination with trastuzumab and pertuzumab for the treatment of metastatic trastuzumab-resistant HER2-enriched breast cancer (NCT03135171).